Treatment of peripheral pain with low-dose local anesthetics by epidermal, epithelial and periosteal application

Thomas Michels1
Seifollah Ahmadi2
Nicole Graf3
1Outpatient Practice, 50968 Cologne (Koeln), Germany; 2Institute of Physiology II, University of Bonn, 53115 Bonn, Germany; 3Graf Biostatistics, CH-8400 Winterthur, Switzerland

Objectives: The efficiency of local anesthetics (LAs) in the treatment of peripheral pain is commonly attributed to their capacity to block the axon conduction of sensory nerves. LAs even in non-blocking concentration suppress oscillations of the resting membrane potential. Spiking in sensory neurons is triggered by subthreshold membrane potential oscillations (SMPOs), which reach threshold and is maintained by depolarizing impulse after oscillations. The suppression of these oscillations abolishes sustained afferent discharge in sensory nerves without blocking the axon conduction. In a retrospective observational study, we examined if LAs in low concentration and very small quantities could reduce peripheral pain in patients.

Design: During a period of 2 years, a total of 127 consecutive patients, 43 with cervico-brachial, 12 with intercostal and 72 with lumbo-sciatic pain received an identical treatment, which consisted of LAs applied in 4–8 sessions on average to a fixed set of epidermal, epithelial and periosteal locations. The primary outcome was relief of symptoms measured by verbal analog scales at the end of therapy.

Results: At the end of therapy, 53 (41.7%) of all patients (127) had a complete remission (reduction of pain 100%). Twenty-three patients (18.1%) had a partial remission with >90% reduction of pain and 50 patients (39.4%) had a pain reduction of 30%–90%. One patient did not respond.

Conclusion: LAs in low concentration and small quantities proved to be highly efficient in the treatment of peripheral pain. An almost complete remission could be obtained in a majority of patients. Given the extent of pain reduction achieved, the method of application seems to be of major importance.

Keywords: non-blocking local anesthetics, subthreshold membrane potential oscillations, acute chronic peripheral and neuropathic pain, alpha 1-adrenoceptors, complex regional pain syndrome

Introduction
It is well known that local anesthetics (LAs) in the treatment of pain are not confined to their capacity to block axon conduction in sensory nerves.1–3 Under normal conditions, action potentials in a sensory neuron are generated from the peripheral nerve ending and conducted axonally to the dorsal cord/CNS. However, injury or inflammation enhances subthreshold membrane potential oscillations (SMPOs) in the peripheral nerve or dorsal root ganglion neuron, which triggers discharge upon reaching threshold. In the laboratory, only sensory neurons of dorsal root ganglia with SMPOs were capable of generating sustained afferent discharge and hence neuropathic paresthesias and pain.
LAs in a concentration much lower than required to block axon conduction are able to suppress these SMPOs and ectopic firing. But these results were gained mainly under laboratory conditions in vitro and in vivo in animals. Our study aimed to examine if a treatment with LAs in lowest concentration and smallest quantities could reduce peripheral pain in patients under the conditions of an outpatient practice.

Patients and methods
Consecutive patients presenting to an outpatient office with neuralgias of peripheral nerves with and without sensory impairment were enrolled into the study. All patients gave consent to be treated with LAs for their symptoms. Exclusion criteria were allergies to LAs, neuralgia with impairment of motor functions or due to a disturbed metabolism (diabetes, nephropathy), to medications, to infections (herpes zoster, HIV), to a spinal cord injury or related to cancer. The sensory and motor function within the treated location of each patient was examined before and after each therapeutic session.

Patients were divided into three groups according to their complaints:
Group 1: patients with cervico-brachial pain (C3-8) spreading to the shoulder and/or arm, ICD10, 2016: M53.1;
Group 2: patients with intercostal pain along the spinal nerves (Th1-10), ICD10: G58.9;
Group 3: patients with lumbo-sciatic pain (Th11-S3), spreading to the lower abdominal wall, the inguinal region and/or into the leg, ICD10: M51.1–2, M54.3–5, G57.1+9.

All groups were differentiated in regard to acute pain (<2 weeks) and chronic pain (≥2 weeks). The dermatomes of the spinal nerves involved and the adjacent dermatomes were treated with injections of LAs in low concentration and small quantities to avoid blocking of axon conduction.

Per site of injection, the LA (mepivacaine 0.5%) was applied in a quantity of 0.1–0.2 mL to the following locations:
(1) Intraepidermal (Figure 1) as superficial wheals of 5–10 mm in diameter to the affected side: a) paravertebral, 1–2 cm lateral of the spinous process, as a proximal access to a dermatome; b) paramedian of the ventral body mid-

Figure 1 Dorsal site of intraepidermal and periosteal injections and ventral site of intraepidermal injections within the segments concerned for the left side of the body.
line, as a distal access to the dermatomes of the trunk and/or c) midline of interdigital skin folds to the dorsal side, as a distal access to the dermatomes of the extremities.

The therapeutic efficiency was increased when – in addition to a proximal access to a dermatome – a distal access to its periphery was used.

(2) Intraepithelial (Figure 2) as a superficial wheal to the palatal velum on both sides.

(3) Periosteal lateral to the spinous process through the epidermal wheal already applied down to the base of the vertebral body perceiving the right depth by bone resistance.

(4) Epidermal scars (in nonresponders) distributed in the midline of the scar over the whole extension and directly under the surface.

In addition to the described procedure in intercostal pain, the LA was applied also directly periosteal to the involved ribs at the site of their highest sensitivity to pressure.

In cases of acute pain, 1–3 sessions/week were performed.

In chronic pain, 2 sessions/week were applied in the beginning followed by increasing phases of remission and corresponding longer intervals between the sessions.

Before therapy, patients classified the strength of their pain as “medium”, “strong” or “very strong”.

The primary endpoint was the change in pain level from prior to first treatment to the end of treatment. The pain level was measured by verbal analog scales during and at the end of therapy with 0% meaning no reduction of pain up to 100% meaning a total reduction. To reduce individual/psychological changes of complaints, we used 4 categories of pain reduction only: 1) 100%, 2) >90%, 3) 90%–30%, 4) <30%.

The Wilcoxon rank sum test was used to compare the pain reduction between patients with acute and chronic pain. As the number of patients with acute and chronic pain was not equally distributed between the three pain groups “cervico-brachial pain”, “intercostal pain” and “lumbo-sciatic pain”, the Kruskal–Wallis test to compare the pain reduction between patients of different pain groups was performed stratified for acute/chronic pain. Moreover, inverse probability weight for acute/chronic pain was computed to perform weighted two-sample rank tests.

Results
One hundred and twenty-seven consecutive outpatients (57 males, 70 females; age range 29–88, mean ± SD=63.17±12.75 years) were enrolled into the study. A total of 43 patients had cervico-brachial pain (group 1; 19 acute; 24 chronic), 12 patients had intercostal pain along the spinal nerves (group 2; 11 acute; 1 chronic) and 72 patients were affected by lumbo-sciatic pain (group 3; 36 acute; 36 chronic).

Before therapy, the strength of pain was classified by ten (7.9%) patients as “very strong”, by 63 (49.6%) patients as “strong” and by 54 (42.5%) as “medium”.

The mean duration of therapy was 9.1 days with 3.8 sessions on average in the acute cases and 25.6 days with 7.1 sessions in the chronic cases.

The primary endpoint, the change in pain level, showed an obvious reduction at the end of treatment. Thus, 53 (41.7%) patients had a complete remission. 23 (18.1%) patients had a partial remission with >90% reduction of pain and 50 (39.4%)
patients showed a partial remission with a pain reduction of 30%--90%. One patient did not respond (Table 1).

Patients with acute pain experienced a higher pain reduction than patients with chronic pain (Figure 3). The difference between their pain reduction was highly significant ($P<0.001$).

There was no significant difference of pain reduction between the three pain groups with an acute onset ($P=0.263$), or between the three pain groups with a chronic onset ($P=0.283$). Likewise, the weighted analysis did not indicate a significant difference between the pain groups (acute+ chronic), neither between patients with cervico-brachial and intercostal pain ($P=0.997$) nor between patients with cervico-brachial and lumbo-sciatic pain ($P=0.332$) or between patients with intercostal and lumbo-sciatic pain ($P=0.720$).

Among the complete remissions, there were three cases of intercostal neuralgia of the abdominal wall = anterior cutaneous nerve entrapment syndrome (Carnett’s test positive),5–8 one case with a displacement of the intervertebral disc (L4/5) and 11 cases with pain projection merely to the knee.

The application of LAs into epidermal scars for non-responders was performed in 33 (25.9%) cases leading to complete remissions in 20 patients.

**Table 1 Absolute and relative frequencies of pain reduction by pain group and acute/chronic pain**

<table>
<thead>
<tr>
<th>Pain reduction (%)</th>
<th>Allogether</th>
<th>Cervico-brachial, acute</th>
<th>Intercostal, acute</th>
<th>Lumbo-sciatic, acute</th>
<th>Cervico-brachial, chronic</th>
<th>Intercostal, chronic</th>
<th>Lumbo-sciatic, chronic</th>
</tr>
</thead>
<tbody>
<tr>
<td>100%</td>
<td>53 (41.7)</td>
<td>9 (47.4)</td>
<td>8 (72.7)</td>
<td>19 (52.8)</td>
<td>4 (16.7)</td>
<td>0 (0.0)</td>
<td>13 (36.1)</td>
</tr>
<tr>
<td>&gt;90%</td>
<td>23 (18.1)</td>
<td>6 (31.6)</td>
<td>3 (27.3)</td>
<td>8 (22.2)</td>
<td>3 (12.5)</td>
<td>0 (0.0)</td>
<td>3 (8.3)</td>
</tr>
<tr>
<td>90%–30%</td>
<td>30 (39.4)</td>
<td>4 (21.1)</td>
<td>0 (0.0)</td>
<td>8 (22.2)</td>
<td>17 (70.8)</td>
<td>1 (100.0)</td>
<td>20 (55.6)</td>
</tr>
<tr>
<td>&lt;30%</td>
<td>1 (0.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>1 (2.8)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
</tbody>
</table>

**Figure 3** Relative frequencies of pain reduction by pain group and acute/chronic pain.
Motor impairments after a therapeutic session as possible results of an unintended conduction block were never observed.

**Discussion**

The results of our study could not have been achieved by pure blockages of the axon conduction of sensory nerves which last only for hours. Furthermore, the very low concentration and quantity of the LA applied, the missing of motor impairments after the application as well as the locations of application make a conduction block as the underlying mechanism of these results unlikely; whereas the ability of LAs to suppress SMPOs even in lowest concentration could explain them, especially the always observed suddenness of pain improvement. So far, these suppressions were provable only under laboratory conditions in animals and not in patients. The results presented show the possible importance of these suppressions of SMPOs for the treatment of peripheral pain with LAs.

The achieved extent of pain reduction and its long duration are also attributed to the special mode of LAs application. It aimed to address not only the sensory afferent limb of pain signals from the periphery to the spinal cord but simultaneously also the sympathetic efferent one from the spinal cord back to the periphery. Strategies for treatment must recognize and aim to eliminate both those factors that are responsible for initiating the vicious circle of maladaptive plasticity and those which perpetuate it.

The presented therapy is characterized by three unusual features.

LAs are applied in low concentration and small quantities. They are administered distal to the structures affected and finally within the dermatomes involved and in the neighboring dermatomes.

Most important for the therapeutic results is the ability of LAs even in non-blocking concentration to suppress resting membrane potential oscillations of nerve cells. Only sensory neurons of dorsal root ganglia with SMPOs are capable of generating sustained afferent discharge and hence neuropathic paresthesias and pain. Spiking in sensory neurons is started by oscillations, which reach the threshold necessary to trigger an action potential and is maintained by depolarizing impulse after oscillations. These oscillations are highly sensitive to LAs even in lowest non-blocking concentration (also to gabapentin) by which they are suppressed and in consequence ectopic firing, paresthesias and pain. The suppression of SMPOs by LAs and the pain reduction starts immediately and lasts much longer (for days or even longer) than after the blockage of nerve conduction by LAs (for hours only).

Regrettably in our study, a late recording of complaints was performed only in seven cases, 11–31 months (on average 17 months) after the end of therapy. All of them had a chronic onset and showed a complete remission, which still lasted.

The SMPOs are also sensitive to epinephrine and norepinephrine, which are able to evoke and increase oscillations and repetitive firing. This seems to be the underlying mechanism of the peripheral sensitization of nociceptors in the skin/epidermis as well as in nerve end neuromas in epidermal scars by sympathetic efferent activity, which is of special importance for the treatment of sensitized scars in nonresponders discussed later.

When applying LAs distal to the structures affected, it should be realized that intraepidermal receptors of pain-mediating afferents are likely to become generators of spontaneous activity after nerve lesions proximal to them.

This increased spontaneous activity distal to the side of the nerve lesion has been proven not only in the affected dermatomes but also in the unaffected neighboring ones. For this reason, not only the dermatomes involved were treated in their periphery but also the adjacent ones.

The LAs were applied to four different structures (epidermal, epithelial, periosteal and into epidermal scars), which seemed to be particularly recommendable by their anatomical characteristics.

The epidermal application in form of superficial wheals was used as an access to afferent sensitive and efferent sympathetic activity.

Afferent sensitive nerve fibers are found in the epidermis in dense distribution and reach all three epidermal layers as free nerve endings frequently branching in bush-like clumps. This high density of very thin afferent nerve fibers in the outer layers of the skin presents a sensitive access for intraepidermal injections of LAs to afferent sensitive activity.

The same application renders simultaneously an access to efferent sympathetic activity arriving from the spinal cord in the periphery.

The augmented activity of epidermal nociceptors after nerve lesions is accompanied by an increased expression of α1-adrenoceptors and consequently also by an abnormal excitability of nociceptive afferents to adrenergic agents which are able to induce and increase SMPOs in those afferents (see above). In addition, the density of α1-adrenoceptors is significantly greater in the hyperalgesic skin of patients than in the skin of normal individuals.
This is of interest in the development of sympathetically maintained pain in conditions such as cutaneous neuromas, amputation stump pain, complex regional pain syndrome and postherpetic neuralgia\(^6,29,30\) since these nociceptors are highly susceptible to LAs and in the form of superficial wheals.\(^27\)

The epithelial application was used as an access to efferent sympathetic activity. The epithelium of the palatal velum represents one of the most dense innervations of the oral mucosa.\(^25\) The palatal epithelium served as a site of LA injections because of its immediate connection to the upper cervical ganglion and thereby to the sympathetic chain as proven by retrograde tracer methods.\(^32,33\) Finally, this location was assumed as an access to sympathetic efferents by the often experienced observation of impressive improvements especially of lumbo-sciatic pains immediately following an application of LAs to the palatal velum.

The periosteal application was used as an access to efferent sympathetic activity. The periosteum, with its sensory and sympathetic nerve fibers, is the most densely innervated tissue of all bone structures.\(^34\) The periosteal sympathetic fibers are derived from and stand in direct connection to the sympathetic chain.\(^35,36\) The LAs were applied to the periosteum of the vertebral column as a further access to the sympathetic chain.

In intercostal neuralgias, the application of LAs directly on the rib at the site of its highest sensitivity to pressure used the periosteal access as well and had by far better results than a conduction blockage of the intercostal nerve with the risk of a pneumothorax.\(^5\)

LAs into epidermal scars were applied in cases of non-responders. Cases of partial or complete failures could be due to epidermal scars within dermatomes involved and/or even in neighboring or contralateral dermatomes.\(^37\) In the superficial area of scars, there are countless cut epidermal afferent nerve endings with a potentially afferent hyperexcitability due to the demyelination at the cut nerve end and hence a Na\(^+\) channel protein accumulation.\(^38-41\) Even after years of silence, these nerve end neuromas can be sensitized by efferent sympathetic activity from the spinal cord to the scar induced by efferent action potentials from the periphery to the spinal cord due to a fresh pain event.\(^37\) Those sensitized neuromas develop the same oscillatory behavior with the same sensitivity to LAs as the peripheral nociceptors in the skin to neurons in the spinal cord and the simultaneous suppression of efferent sympathetic activity from these neurons back to the peripheral nociceptors in the skin. These processes were demonstrated under laboratory conditions with animals in vitro and in vivo only. To our knowledge, there are no studies so far to show the efficiency of LAs in very low concentration and quantity in the treatment of peripheral pain in patients. It is not surprising therefore that many questions remain open. For instance, the long duration of the suppression of membrane potential oscillations, which last much longer than an axon conduction block due to LAs.\(^5,22,37,44,50-52\) the rapid action of nonblocking LAs also in dissipating central sensitization and allodynia within minutes\(^45\) and after their repeated application the increasing length of remissions.\(^43-45,50,51\)

**Conclusion**

The presented results demonstrate a high efficiency of low-dose LAs in the reduction of peripheral pain most likely due to a suppression of SMPOs in neurons blocking sensitive afferent activity from the periphery to the spinal cord and simultaneously efferent sympathetic activity from the spinal cord back to the periphery. The possible contribution of activated nerve end neuromas in scars to this maladaptive circle of plasticity is emphasized and it is shown how to inactivate it. Due to the complexity of the mechanisms of peripheral
pain, the theory and method of this treatment leave many questions open.

The strength of these data is that they were observed under routine conditions of a normal outpatient practice. A shortcoming is the lack of a control group. However, the results of this therapy with its simplicity of application, negligible side effects, very low costs and often fast improvements even in neuropathic pain conditions, where alternatives rarely exist, are so encouraging that a clarification of the remaining questions by further laboratory and clinical studies seems to be a worthwhile recommendation.

Acknowledgment

This study was approved by the ethics committee Ärztekammer Nordrhein, Düsseldorf, with a waiver of patients consent as all data were anonymized.

Disclosure

The authors report no conflicts of interest in this work.

References


